MS Clinical Trials in Pennsylvania

31 active trials · 13 recruiting

31 active multiple sclerosis clinical trials have at least one study site in Pennsylvania, 13 of them currently recruiting participants. Trials are listed from ClinicalTrials.gov and cover disease-modifying therapies, symptom treatments, rehabilitation and imaging studies.

Eligibility, contact details and the exact site address are on each trial's ClinicalTrials.gov record, linked from every trial page. MS Buddy also lists 15 MS treatment centers in Pennsylvania; many trial sites are run from those centers, and your neurologist is the best first person to ask about joining a study.

Active MS trials with sites in Pennsylvania

RecruitingPhase 1

Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer

Sponsor: National Cancer Institute (NCI)

Biospecimen Collection · Nivolumab

19 states300 participantsDetails ›

RecruitingPhase 2

A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity

Sponsor: Celgene

BMS-986368 · Placebo

11 states200 participantsDetails ›

RecruitingPhase 4

Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Ocrelizumab · Placebo for Ocrelizumab

9 states123 participantsDetails ›

RecruitingPhase 3

Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis

Sponsor: Sanofi

Frexalimab · Teriflunomide

35 states1600 participantsDetails ›

Recruiting

A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)

Sponsor: TG Therapeutics, Inc.

No Intervention

29 states500 participantsDetails ›

RecruitingPhase 3

Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis

Sponsor: Sanofi

Frexalimab · Placebo

38 states900 participantsDetails ›

RecruitingNA

Central Vein Sign in Multiple Sclerosis Extension Study

Sponsor: The Cleveland Clinic

MRI Contrast

3 states40 participantsDetails ›

RecruitingPhase 3

Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Autologous Hematopoietic Stem Cell Tr… · Best Available Therapy (BAT)

15 states156 participantsDetails ›

Recruiting

Prospective Investigation of Multiple Sclerosis in the Three Rivers Region

Sponsor: University of Pittsburgh

1 state7500 participantsDetails ›

Recruiting

A Biospecimen Collection Study to Identify the Targets of Disease-Reactive T Cells in Patients With Autoimmune Disease

Sponsor: TScan Therapeutics, Inc.

Companion blood samples with procedure

9 states300 participantsDetails ›

RecruitingPhase 2

A Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis Patients

Sponsor: Tiziana Life Sciences LTD

Foralumab · Placebo

5 states54 participantsDetails ›

Recruiting

Genes and Environment in Multiple Sclerosis

Sponsor: Columbia University

4 states5000 participantsDetails ›

Recruiting

Obesity and Pediatric Multiple Sclerosis

Sponsor: University of Virginia

2 states116 participantsDetails ›

By invitation onlyNA

Immune Profiles in Multiple Sclerosis (MS) Patients and Healthy Volunteers Through Thoracic Duct Cannulation

Sponsor: University of Pennsylvania

thoracic duct cannulation

1 state24 participantsDetails ›

By invitation onlyNA

Physiological Effects of N-Acetyl Cysteine in Patients With Multiple Sclerosis

Sponsor: Thomas Jefferson University

N-acetyl Cysteine

1 state55 participantsDetails ›

Closed to new patientsPhase 3

Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)

Sponsor: Novartis Pharmaceuticals

Remibrutinib · Teriflunomide

23 states1011 participantsDetails ›

Closed to new patientsPhase 3

Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis

Sponsor: Novartis Pharmaceuticals

Fingolimod · Ofatumumab

6 states129 participantsDetails ›

Closed to new patientsPhase 3

Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of a New Maintenance Dosing Regimen of Ofatumumab

Sponsor: Novartis Pharmaceuticals

Ofatumumab approved dose · Ofatumumab new dose

24 states196 participantsDetails ›

Closed to new patientsPhase 3

Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)

Sponsor: Novartis Pharmaceuticals

Remibrutinib · Teriflunomide

27 states1001 participantsDetails ›

Closed to new patientsPhase 3

Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS

Sponsor: Novartis Pharmaceuticals

Ofatumumab · Tetanus toxoid (TT) containing vaccin…

32 states1882 participantsDetails ›

Closed to new patientsPhase 3

A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis

Sponsor: Hoffmann-La Roche

Ocrelizumab · Placebo

5 states1013 participantsDetails ›

Closed to new patientsPhase 3

A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)

Sponsor: Hoffmann-La Roche

Fenebrutinib · Teriflunomide

23 states746 participantsDetails ›

Closed to new patientsPhase 3

A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)

Sponsor: Hoffmann-La Roche

Ocrelizumab · Ocrelizumab

20 states864 participantsDetails ›

Closed to new patientsPhase 3

A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis

Sponsor: Hoffmann-La Roche

Ocrelizumab

26 states1300 participantsDetails ›

Closed to new patientsPhase 3

A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis (RRMS)

Sponsor: Hoffmann-La Roche

Ocrelizumab · Ocrelizumab Placebo

11 states188 participantsDetails ›

Closed to new patientsPhase 3

A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis

Sponsor: Hoffmann-La Roche

Ocrelizumab

13 states927 participantsDetails ›

Closed to new patientsPhase 3

Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis

Sponsor: Novartis Pharmaceuticals

Interferon beta-1a · Fingolimod

8 states240 participantsDetails ›

Closed to new patientsNA

Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial

Sponsor: Johns Hopkins University

Natalizumab/natalizumab-sztn, Alemtuz… · Glatiramer acetate, Interferons (intr…

28 states900 participantsDetails ›

Closed to new patients

Central Vein Sign: a Diagnostic Biomarker in Multiple Sclerosis

Sponsor: The Cleveland Clinic

MRI

9 states420 participantsDetails ›

Closed to new patientsNA

ATOMIC (Active Teens Multiple Sclerosis) Physical Activity Research Program

Sponsor: The Hospital for Sick Children

Physical Activity (PA) Intervention · Waitlist attention-control

2 states56 participantsDetails ›

Closed to new patients

Portable Neuromodulation Stimulator Registry for People With Multiple Sclerosis

Sponsor: Helius Medical Inc

Portable Neuromodulation Stimulator (…

1 state150 participantsDetails ›

The app

Check out the MS Buddy app

Track symptoms, monitor wellness, and stay on top of your MS care. It’s free, with no ads. Built by people living with MS.

Active MS trials with sites in Pennsylvania

MS trials in other states